IL-1-driven stromal–neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies

Matthias Friedrich(Nuffield Orthopaedic Centre), Michael B. Brenner(Brigham and Women's Hospital), Sarah McCuaig(Nuffield Orthopaedic Centre), Hannah Sharpe(University of Oxford), Matthew Jackson(King's College London), Kévin Rue-Albrecht(Hammersmith Hospital), Samuel J. Bullers(Nuffield Orthopaedic Centre), Rahul Ravindran(John Radcliffe Hospital), Ruchi Tandon(Translational Health Science and Technology Institute), Dharshan Sathananthan(John Radcliffe Hospital), Kara G. Lassen(Roche (Switzerland)), Mark Coles(University of Oxford), Ilya Korsunsky(Broad Institute), Kevin Wei(Brigham and Women's Hospital), Raphael Sanches Peres, Elizabeth H. Mann(Nuffield Orthopaedic Centre), Alessandra Geremia(University of Oxford), Zoe Christoforidou(John Radcliffe Hospital), Christopher D. Buckley(University of Birmingham), Moustafa Attar(Centre for Human Genetics), Holm H. Uhlig(University of Oxford), Mathilde Pohin(Nuffield Orthopaedic Centre), Tom Thomas(Nuffield Orthopaedic Centre), Simon Travis(John Radcliffe Hospital), Francesca Barone(Celldex Therapeutics (United States)), Gerald F. Watts(The University of Western Australia), Soumya Raychaudhuri(Broad Institute), Alistair Easton(Manchester Academic Health Science Centre), Stephen N. Sansom(Nuffield Orthopaedic Centre), Elena Collantes(John Radcliffe Hospital), Andreas P. Frei(Roche (Switzerland)), Lloyd Thomas(John Radcliffe Hospital)
Nature Medicine
October 21, 2021
Cited by 289


Related Papers